Investigate the levels of soluble vascular cell adhesion molecule 1 (sVCAM-1) and intercellular adhesion molecule 1 (sICAM-1) in the sera of patients with rheumatoid arthritis

Authors

  • Aseel Jawad Kadim College of Education for Pure Sciences / University of Diyala
  • Ammar A. Sultan

DOI:

https://doi.org/10.24237/04.01.598

Keywords:

VCAM-1, ICAM-1, Rheumatoid arthritis, Anti-CCP, ESR

Abstract

Rheumatoid arthritis (RA) is an autoimmune disorder, the synovial joint becomes inflamed and eventually erosive, causing damage to the bones and cartilage. The study aimed to evaluated vascular cell adhesion molecule1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) serum levels in RA patients. These cellular adhesion molecules (CAMs') serum levels may indicate endothelial cell expression and a possible relationship with other variables. Eighty-eight volunteers, 50 RA patients and 38 healthy controls, ranging in age from 25 to 75, were assessed. The levels of biomarkers were examined in this study: CAM-1, VCAM-1, Rheumatoid Factor (RF), Anti-CCP, C-reactive protein (CRP), ESR, and erythrocyte sedimentation rate (ESR). The findings indicate that there is a significant variation (p≤0.001) in the levels of RF, Anti-CCP, CRP, and ESR between individuals with RA patients and the control group. Moreover, it was observed that there exist there exist substantial disparities (p≤0.001) in the concentrations of VCAM-1 between the subjects diagnosed with rheumatoid arthritis (RA) and the control cohort. Furthermore, it was observed that the concentration of ICAM-1 in patients with RA was significantly elevated (p≤0.001) when juxtaposed with the control cohort. Conversely, the results suggested a correlation that lacked statistical significance between the concentrations of ICAM-1 and VCAM-1 and the serological parameters. In the present investigation, we concluded that elevated levels of VCAM-1 and ICAM-1 in individuals with RA may serve as potential biomarkers for the diagnosis and prognostication of RA, as well as a contributory factor in the pathogenesis of RA as an inflammatory disorder.

Downloads

Download data is not yet available.

References

[1] G. I. Ibrahim, S. M. Abdulkareem, and L. M. Hasan, “Concentration of NO, C-Reactive Protein, Magnesium, Calcium, and Phosphorous in Patients with Arthritis,” Diyala Journal of Medicine, vol. 15, no. 2, pp. 23–31, 2018, doi: 10.26505/DJM.

[2] B. Hassan, A. J. Kadim, and A. A. Sultan, “Study of some immunological indicators of interleukin-9 in rheumatoid arthritis of Iraqi patients,” Journal of Physics: Conference Series, IOP Publishing, 2020, doi: 10.1088/1742-6596/1660/1/012010.

[3] E. R. Sarhat, A. R. Sarhat, Z. N. Mustafa, and S. A. Wadi, “Evaluation of the salivary oxidative stress and non-enzymatic antioxidants marker in patients with rheumatoid arthritis,” Tikrit Journal for Dental Sciences, vol. 7, no. 1, pp. 27–30, 2019, doi: 10.25130/tjds.7.1.4.

[4] J. Kadim, A. A. Sultan, and I. B. Hassan, “A genetic polymorphism of interleukin-9 gene (rs2069882) in rheumatoid arthritis of Iraqi patients,” Biochemical & Cellular Archives, vol. 19, no. 2, 2019, doi: 10.35124/bca.2019.19.2.3613.

[5] W. F. Hussain and W. K. H. Al-Hashemi, “Effect of oxidative stress on Iraqi rheumatoid arthritis patients,” Al-Nahrain Journal of Science, vol. 21, no. 2, pp. 28–31, 2018, doi: 10.22401/JNUS.21.2.04.

[6] E. A. Abdulrahman, H. Demir, and B. K. Aziz, “Determination of malondialdehyde (MDA) and some antioxidant activities in rheumatoid arthritis patients,” Journal of Kufa for Chemical Sciences, vol. 2, no. 10, pp. 122–136, 2023.

[7] Z. A. G. Al-Ghuraibawi, I. K. Sharquie, and F. I. Gorial, “A novel link of serum IL-39 levels in patients with rheumatoid arthritis,” Iraqi Journal of Science, pp. 1651–1661, 2023, doi: 10.24996/ijs.2023.64.4.8.

[8] N. Abdul Mohaimen, A. Sami, and Z. T. S. Al-Assady, “Intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in hypertensive patients suffering from bacterial UTIs,” Karbala Journal of Pharmaceutical Sciences, no. 5, 2013.

[9] R. A. Abdullah and I. S. Abdulrahman, “Circulating cell adhesion molecules level in type 2 diabetes mellitus and its correlation with glycemic control and metabolic syndrome: A case-control study,” Medical Journal of Babylon, vol. 20, no. 1, pp. 64–70, 2023, doi: 10.4103/MJBL.MJBL-246-22.

[10] Z. T. S. Al-Assady, “Intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in hypertensive patients suffering from bacterial UTIs,” Karbala Journal of Pharmaceutical Sciences, vol. 4, no. 5, pp. 56–68, 2013.

[11] M. Salih, I. N. Salman, and R. M. Kaduhm, “Study ABO/Rh system with endothelial inflammatory factors in Iraqi Arab female with diabetes mellitus type II,” Baghdad Science Journal, vol. 11, no. 1, pp. 93–102, 2014, doi: 10.21123/bsj.2014.11.1.93-102.

[12] K. Y. Yu, S. Yung, M. K. Chau, C. S. Tang, D. Y. Yap, A. H. Tang, and K. N. Lai, “Clinico-pathological associations of serum VCAM-1 and ICAM-1 levels in patients with lupus nephritis,” Lupus, vol. 30, no. 7, pp. 1039–1050, 2021, doi: 10.1177/09612033211004727.

[13] H. W. Khammas, G. H. Abdulhadi, and M. H. Munshid, “Levels of VCAM-1 and ICAM-1 in serum of active and inactive systemic lupus erythematosus patients as biochemical markers for risk of cardiovascular disease,” Journal of the Faculty of Medicine Baghdad, vol. 65, no. 4, 2024, doi: 10.32007/jfacmedbagdad.1952.

[14] G. A. Hegazy, Z. Awan, E. Hashem, N. Al-Ama, and A. B. Abunaji, “Levels of soluble cell adhesion molecules in type 2 diabetes mellitus patients with macrovascular complications,” Journal of International Medical Research, vol. 48, no. 4, 2020, doi: 10.1177/0300060519893858.

[15] D. Aletaha, T. Neogi, A. J. Silman, J. Funovits, D. T. Felson, C. O. Bingham III, N. S. Birnbaum, G. R. Burmester, V. P. Bykerk, M. D. Cohen, B. Combe, K. H. Costenbader, M. H. Dougados, P. Emery, G. Ferraccioli, J. M. Hazes, K. Hobbs, T. W. Huizinga, A. Kavanaugh, J. Kay, T. K. Kvien, T. Laing, P. Mease, H. A. Ménard, L. W. Moreland, R. Naden, T. Pincus, J. S. Smolen, E. Stanislawska-Biernat, D. Symmons, P. P. Tak, K. S. Upchurch, J. Vencovský, F. Wolfe, and G. Hawker, “2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative,” Arthritis & Rheumatism, vol. 62, no. 9, pp. 2569–2581, 2010, doi: 10.1002/art.27584.

[16] R. Shen, X. Ren, R. Jing, X. Shen, J. Chen, S. Ju, and J. Wu, “Rheumatoid factor, anti-cyclic citrullinated peptide antibody, C-reactive protein, and erythrocyte sedimentation rate for the clinical diagnosis of rheumatoid arthritis,” Laboratory Medicine, vol. 46, no. 3, pp. 226–229, 2015, doi: 10.1309/LMZYTSO5RHIHV93T.

[17] S. A. Alwan, R. A. Abdul-Ridha, and A. I. Ali, “Assessment of plasma level of CTHRC-1 in patients with rheumatoid arthritis,” Iraqi Journal of Medical Sciences, vol. 19, no. 2, 2021, doi: 10.22578/IJMS.19.2.8.

[18] A. Wahab, M. Mohammad, M. Rahman, and M. S. M. Said, “Anti-cyclic citrullinated peptide antibody is a good indicator for the diagnosis of rheumatoid arthritis,” Pakistan Journal of Medical Sciences, vol. 29, no. 3, p. 773, 2013, doi: 10.12669/pjms.293.2924.

[19] H. M. Hussien and R. M. Abed, “Determination of miRNA-34a expression in rheumatoid arthritis,” The Egyptian Journal of Hospital Medicine, vol. 90, no. 1, pp. 1413–1420, 2023, doi: 10.21608/ejhm.2023.282167.

[20] R. Ahmad and A. Zgair, “Immunological and biological manifestation of rheumatoid arthritis patient in Iraq,” Indian Journal of Forensic Medicine & Toxicology, vol. 15, no. 4, pp. 1344–1350, 2021, doi: 10.37506/ijfmt.v15i4.16896.

[21] S. I. Mohammed, M. Y. Jamal, and I. O. Alshamari, “The association of genetic polymorphisms in tumor necrosis factor-alpha and interleukins with disease severity or response to biological therapy in Iraqi rheumatoid arthritis patients: A narrative review,” Al-Rafidain Journal of Medical Sciences, vol. 4, pp. 24–33, 2023, doi: 10.54133/ajms.v4i.100.

[22] K. Wierzchosławski, K. Kwit, Z. Pejsak, M. Pomorska-Mól, “Selected serum acute-phase proteins in peripartum sows and evaluation of their diagnostic usefulness,” Animal Reproduction Science, vol. 191, pp. 44–55, 2018, doi: 10.1016/j.anireprosci.2018.02.003.

[23] T. Sokka and T. Pincus, “Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%–45% of patients with rheumatoid arthritis,” The Journal of Rheumatology, vol. 36, no. 7, pp. 1387–1390, 2009, doi: 10.3899/jrheum.080770.

[24] E. Kassem, L. Mahmoud, and W. Salah, “Study of resistin and YKL-40 in rheumatoid arthritis,” Journal of American Science, vol. 6, no. 10, pp. 1004–1012, 2010.

[25] H. R. Salem and E. S. Zahran, “Vascular cell adhesion molecule-1 in rheumatoid arthritis patients: Relation to disease activity, oxidative stress, and systemic inflammation,” Saudi Medical Journal, vol. 42, no. 6, p. 620, 2021, doi: 10.15537/smj.2021.42.6.20200753.

[26] K. Södergren, K. Karp, C. Bengtsson, B. Möller, S. Rantapää-Dahlqvist, and S. Wållberg-Jonsson, “Biomarkers associated with cardiovascular disease in patients with early rheumatoid arthritis,” PLoS One, vol. 14, no. 8, e0220531, 2019, doi: 10.1371/journal.pone.0220531.

[27] G. Denys, G. Clavel, D. Lemeiter, O. Schischmanoff, M. C. Boissier, and L. Semerano, “Aortic VCAM-1: An early marker of vascular inflammation in collagen-induced arthritis,” Journal of Cellular and Molecular Medicine, vol. 20, no. 5, pp. 855–863, 2016, doi: 10.1111/jcmm.12788.

[28] R. Hasseli, K. W. Frommer, M. Schwarz, M.-L. Hülser, C. Schreiyäck, M. Arnold, E. Neumann, S. Müller-Ladner, and U. Lange, “Adipokines and inflammation alter the interaction between rheumatoid arthritis synovial fibroblasts and endothelial cells,” Frontiers in Immunology, vol. 11, p. 925, 2020, doi: 10.3389/fimmu.2020.00925.

[29] D.-H. Kong, Y. K. Kim, M. R. Kim, J. H. Jang, and S. Lee, “Emerging roles of vascular cell adhesion molecule-1 (VCAM-1) in immunological disorders and cancer,” International Journal of Molecular Sciences, vol. 19, no. 4, p. 1057, 2018, doi: 10.3390/ijms19041057.

[30] H. Harjunpää, M. Llort Asens, C. Guenther, and S. C. Fagerholm, “Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment,” Frontiers in Immunology, vol. 10, p. 1078, 2019, doi: 10.3389/fimmu.2019.01078.

[31] S. Vidjaya and Y. A. Valentinovich, “Soluble molecules of immunoglobulin superfamily in rheumatoid arthritis,” Medical Bulletin of the North Caucasus, vol. 12, no. 3, pp. 256–260, 2017, doi: 10.14300/mnnc.2017.12078.

[32] Y. Liu, W. Wei, C. Hong, Y. Wang, X. Sun, J. Ma, Y. Chen, and J. Shen, “Calreticulin induced endothelial ICAM-1 up-regulation associated with tristetraprolin expression alteration through PI3K/Akt/eNOS/p38 MAPK signaling pathway in rheumatoid arthritis,” Molecular Immunology, vol. 107, pp. 10–20, 2019, doi: 10.1016/j.molimm.2018.12.012.

[33] R. Kaur, V. Singh, P. Kumari, R. Singh, H. Chopra, and T. B. Emran, “Novel insights on the role of VCAM-1 and ICAM-1: Potential biomarkers for cardiovascular diseases,” Annals of Medicine and Surgery, vol. 84, 2022, doi: 10.1016/j.amsu.2022.104371.

[34] D. Bedeković, I. Bošnjak, S. Šarić, D. Kirner, and S. Novak, “Role of inflammatory cytokines in rheumatoid arthritis and development of atherosclerosis: A review,” Medicina, vol. 59, no. 9, p. 1550, 2023, doi: 10.3390/medicina59091550.

[35] R. E. Navarro-Hernández, E. Oregon-Romero, M. V.-D. Mercado, H. Rangel-Villalobos, C. A. Palafox-Sánchez, and J. F. Muñoz-Valle, “Expression of ICAM1 and VCAM1 serum levels in rheumatoid arthritis clinical activity: Association with genetic polymorphisms,” Disease Markers, vol. 26, no. 3, pp. 119–126, 2009, doi: 10.3233/DMA-2009-0621.

[36] B. Coll-Vinent, C. Vilardell, C. Font, J. Oristrell, J. Hernández-Rodríguez, J. Yagüe, M. A. González, and J. M. Grau, “Circulating soluble adhesion molecules in patients with giant cell arteritis. Correlation between soluble intercellular adhesion molecule-1 (sICAM-1) concentrations and disease activity,” Annals of the Rheumatic Diseases, vol. 58, no. 3, pp. 189–192, 1999, doi: 10.1136/ard.58.3.189.

.

Downloads

Published

2026-01-30

How to Cite

Jawad Kadim, A., & A. Sultan, A. . (2026). Investigate the levels of soluble vascular cell adhesion molecule 1 (sVCAM-1) and intercellular adhesion molecule 1 (sICAM-1) in the sera of patients with rheumatoid arthritis. ٍِASJ - Academic Science Journal, 4(1), 119-125. https://doi.org/10.24237/04.01.598

Similar Articles

1-10 of 110

You may also start an advanced similarity search for this article.